First Trust NYSE Arca Biotechnology Index Fund
Why Exelixis Stock Soared 46% in November
Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
A Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.
Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.
How Vertex Pharmaceuticals Is Positioned Financially
In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million.
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
Incyte’s Revenue Stream in Q2 2018
Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year).
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.
Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.
Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
What Analysts Think about Ionis
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
Ionis Pharmaceuticals Stock as of March 27, 2018
Ionis Pharmaceuticals stock has fallen 6.9% over the last week. However, it rose 2.6% to close at $48.99 on March 26, 2018.
A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.
Nektar Therapeutics Sees Setbacks in Plans for Ciproflaxin DPI
On November 16, 2017, the FDA’s Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics’ ciprofloxacin DPI.
Alnylam Is Preparing for Commercial Launch of Patisiran
To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.
Geographic Market Expansion to Boost Spinraza Sales in 2017
In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.
How Gilead’s Other Products Performed in 2Q17
Apart from Gilead Sciences’ (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio.
Nuplazid Expected to Become a Leading Central Nervous System Drug
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
Ionis Reports Revenue Growth in 2Q17
Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.
The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.
Neurocrine Biosciences: Ingrezza, Collaborations, Ratings
In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.
What Analysts Recommend for United Therapeutics in June 2017
Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”
Ionis Pharmaceuticals’ Valuation Compared to Its Peers
According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
United Therapeutics: Will RemoSynch Become a Key Growth Driver?
United Therapeutics (UTHR) has developed a targeted strategy for a successful launch of its investigational drug device combination, the RemoSynch implantable pump system.
Why Neurocrine Biosciences May See Higher Losses in 2016
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.
How Could Gilead Sciences Restore Its Growth?
With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.
What Drove Regeneron’s 3Q16 Performance?
In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.
What Are the Drivers behind the Success of Soliris?
Following analysts’ projections, Soliris revenues in 3Q16 and 4Q16 should rise 9.0% and 10.0%, respectively, YoY to reach $725.9 million and $760.6 million, respectively.
Why Europe Is an Important Market for Vertex’s Orkambi
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.
How Regeneron Is Working to Maintain Eylea’s Dominance
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.
BioMarin to Cross $1 Billion Revenue in 2016
BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.
Higher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.
What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?
During its 2Q16 earnings call, BioMarin revised its 2016 revenue guidance. It now expects revenue to be $1.1 billion–$1.15 billion.
How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16?
With the continued uptake of Orkambi along with the label expansion efforts, Vertex Pharmaceuticals’s (VRTX) top line in fiscal 2016 is expected to reach $1.7 billion–$1.8 billion.
How Can Alexion Stay ahead of the Competition with Soliris?
Soliris is Alexion Pharmaceuticals’ anchor of success. The drug was approved for paroxysmal nocturnal hemoglobinuria, or PNH, as a first indication in 2007.
ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.
Inside BioMarin’s Big Plans for 3Q16
BioMarin decided to withdraw its MAA (Marketing Authorization Application), given the expectation of a negative decision on the drug from the EMA.
Understanding Alexion’s Robust Pipeline
Alexion is expanding the label for its key drug Soliris. Along with Soliris, Alexion’s has several other key molecules in the advanced development stage.
Why United Therapeutics’ Adcirca Could Witness Strong Revenue Growth
After acquiring commercial rights from Eli Lily (LLY) in 2008, United Therapeutics (UTHR) started marketing Adcirca in the US in 2009.
Medivation Is for Sale: How Much Should It Get?
Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.
How Can Regeneron Pharmaceuticals Boost Revenue from Praluent?
During the first quarter of 2016, Praluent sales came to $13 million.
Understanding Alexion’s Share Price Performance since Its Previous Earnings
Alexion reported a revenue decline of 1.5% and an earnings decline of 2.2% in 1Q16, which surprised investors and led to a 6% fall in its share price.
A Look at Vertex’s Cystic Fibrosis Patient Opportunity
There are ~27,000 eligible patients for Vertex Pharmaceuticals’ Kalydeco and Orkambi. However, Vertex is only currently treating one-third of patients.
Seattle Genetics’ Valuation: How Does It Compare?
We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.
Could Xtandi’s Use for Breast Cancer Be a Valuation Driver?
If Xtandi is successful in achieving a longer treatment duration of about ten months, it could earn up to $1 billion in the breast cancer space.
Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know
Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.
BioMarin’s Naglazyme Sales Dipped by 31.3% Last Year
In 2015, Naglazyme contribution toward BioMarin Pharmaceutical’s (BMRN) total revenue was ~$303 million, down 31.3% YoY.
What’s Vertex’s Label Expansion Strategy for Orkambi?
In November 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received approval from the European Commission to treat patients 12 years and older with two copies of the F508del mutation.
Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15
Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.
How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.
Will Regeneron’s Earnings Continue to Impress Investors?
Regeneron’s net margin during 3Q15 was ~18.5%. Historically, the net margin has been very volatile. It fluctuated from 8% to 24% for the last ten quarters.
Orkambi: Recent Addition to the Vertex Portfolio
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.
Pomalyst and Abraxane Revenues Are Critical for Celgene
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.
Cepheid’s Revenue and Income Fell in 3Q15
After its 3Q15 earnings report, Cepheid fell by 0.86% to close at $32.25 per share as of October 20, 2015, with a 4.8% fall in revenue in 3Q15.
Alkermes’s Multi-Pronged Strategy for Its Aristada Launch
Alkermes plans a multi-pronged strategy for Aristada’s successful launch, which will involve flexible usage, effective pricing, and additional research.